Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120g/L with darbepoetin alfa±filgrastim or erythrocyte transfusions

European Journal of Haematology

Volumn 87, Issue 3, 2011, Pages 244-252

  Nilsson Ehle, Herman ^a   Birgegård, Gunnar ^b   Samuelsson, Jan ^c   Antunovic, Petar ^d   Astermark, Jan ^e   Garelius, Hege ^a   Engström, Lena M ^f   Kjeldsen, Lars ^g   Nilsson, Lars ^e   Olsson, Anna ^a   Skov Holm, Mette ^h   Wallvik, Jonas ⁱ   Gulbrandsen, Nina ^j   Hellström Lindberg, Eva ^k  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g Rigshospitalet   (Denmark)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ SUNDSVALL HOSPITAL   (Sweden)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Anaemia; Elderly; Erythropoietin; Myelodysplasia; Transfusion

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL ARTICLE; CONSTIPATION; DRUG SAFETY; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; IRON OVERLOAD; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SOCIAL INTERACTION; SPIROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; FERRITINS; FILGRASTIM; HEMOGLOBINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84860405224     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01654.x     Document Type: Article

References (38)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
2. World Health Organization. Nutritional anaemias. Report of a WHO scientific group. In WHO Techn Rep 1968;Series No 405, Geneva.
3. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002;87:1286-306.
4. Kjeldsen L, Dybedal I, Garelius H, Juvonen E, Nilsson L, Reykdal S, Skov Holm M, Garelius H, Hellström Lindberg E. Treatment with EPO/darbepoetin alone or in combination with G-CSF for the anemia of MDS. Guidelines for the diagnosis and treatment of the myelodysplastic syndromes and chronic myelomonocytic leukemia wwwnmdsorg: Nordic MDS Group; 2010:19-21.
5. Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw 2008;6:902-26.
6. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46.
7. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106:803-11.
8. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607-13.
9. Giraldo P, Nomdedeu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:2807-16.
10. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513-9.
11. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-93.
12. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527-36.
13. Oliva EN, Nobile F, Alimena G, et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010;51:1007-14.
14. Jakob A, Hirsch FW, Engelhardt M. Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim. Ann Hematol 2005;84:694-5.
15. Rose S, Ali Y, Maffei B, Saidi P. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor. Am J Hematol 2007;82:245-6.
16. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009;84:15-20.
17. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270-4.
18. Clavio M, Nobili F, Balleari E, et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol 2004;72:113-20.
19. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167-76.
20. Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006;85:174-80.
21. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321-7.
22. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S, Guralnik JM, Ferrucci L. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004;52:719-24.
23. Penninx BW, Pluijm SM, Lips P, Woodman R, Miedema K, Guralnik JM, Deeg DJ. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005;53:2106-11.
24. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
25. Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007;138:587-93.
26. Konen E, Ghoti H, Goitein O, Winder A, Kushnir T, Eshet Y, Rachmilewitz E. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007;82:1013-6.
27. Park J, Ohyashiki K, Akata S, Takara K, Uno R, Kakizaki D, Miyazawa K, Kimura Y, Tokuuye K. Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging. Leuk Res 2009;33:756-8.
28. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
29. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC Press, 2003:61-73.
30. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981;64:1227-34.
31. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92:68-75.
32. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
33. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
34. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone+alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94:324-32.
35. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995;13:1249-54.
36. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
37. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008;83:858-61.
38. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008;88:24-9.